Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16064132 | 1.00 | AAK1 (0.40) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL17483621 | 0.91 | AAK1 (0.43) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL3176533 | 0.89 | AAK1 (0.41) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL3176523 | 0.89 | AAK1 (0.41) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL3176530 | 0.89 | AAK1 (0.41) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL496007 | 0.89 | NFE2L2 (0.35) | RAB9AKMT2AKDM4EPOLBMAPT | |
| SCHEMBL496006 | 0.89 | NFE2L2 (0.35) | RAB9AKMT2AKDM4EPOLBMAPT | |
| SCHEMBL18867932 | 0.87 | MEN1 (0.34) | AAK1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL12667355 | 0.86 | AAK1 (0.38) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL17118206 | 0.86 | KDM4E (0.36) | NPC1RAB9AKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697400-B1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AICURIS GMBH & CO KG (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-7655643-B2 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2010-02-02 | — | — | US | disclosed |
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | NOD2, AHR, BCL2 | AAK1 4116/4885NPC1 851/4885RECQL 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.